<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>PGx Clinical Report — PGX019</title>
<style>
  :root {
    --navy: #1a365d;
    --navy-light: #2c5282;
    --slate: #475569;
    --gray-50: #f8fafc;
    --gray-100: #f1f5f9;
    --gray-200: #e2e8f0;
    --gray-300: #cbd5e1;
    --gray-600: #475569;
    --gray-800: #1e293b;
    --critical: #dc2626;
    --critical-bg: #fef2f2;
    --high: #ea580c;
    --high-bg: #fff7ed;
    --moderate: #d97706;
    --moderate-bg: #fffbeb;
    --low: #16a34a;
    --low-bg: #f0fdf4;
    --info: #2563eb;
    --info-bg: #eff6ff;
    --white: #ffffff;
  }

  * { margin: 0; padding: 0; box-sizing: border-box; }

  body {
    font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, sans-serif;
    color: var(--gray-800);
    background: var(--white);
    font-size: 13px;
    line-height: 1.5;
  }

  .page {
    max-width: 1000px;
    margin: 0 auto;
    padding: 0 24px;
  }

  /* HEADER */
  .report-header {
    background: linear-gradient(135deg, var(--navy) 0%, var(--navy-light) 100%);
    color: white;
    padding: 28px 32px;
    display: flex;
    justify-content: space-between;
    align-items: center;
  }
  .report-header .company-name {
    font-size: 22px;
    font-weight: 700;
    letter-spacing: 0.5px;
  }
  .report-header .company-sub {
    font-size: 12px;
    opacity: 0.85;
    margin-top: 2px;
  }
  .report-header .report-meta {
    text-align: right;
    font-size: 11px;
    line-height: 1.6;
  }
  .report-header .report-id {
    font-weight: 600;
    font-size: 13px;
  }

  .confidential-bar {
    background: var(--critical);
    color: white;
    text-align: center;
    font-size: 10px;
    font-weight: 700;
    letter-spacing: 2px;
    padding: 4px 0;
  }

  /* SECTIONS */
  .section {
    margin: 24px 0;
    border: 1px solid var(--gray-200);
    border-radius: 6px;
    overflow: hidden;
  }
  .section-header {
    background: var(--navy);
    color: white;
    padding: 10px 20px;
    font-size: 14px;
    font-weight: 600;
    letter-spacing: 0.3px;
  }
  .section-body {
    padding: 20px;
  }

  /* PATIENT DEMOGRAPHICS */
  .demographics-grid {
    display: grid;
    grid-template-columns: repeat(4, 1fr);
    gap: 12px;
  }
  .demo-item {
    padding: 8px 12px;
    background: var(--gray-50);
    border-radius: 4px;
  }
  .demo-label {
    font-size: 10px;
    font-weight: 600;
    color: var(--slate);
    text-transform: uppercase;
    letter-spacing: 0.5px;
  }
  .demo-value {
    font-size: 14px;
    font-weight: 500;
    margin-top: 2px;
  }

  /* RISK SUMMARY */
  .risk-banner {
    display: flex;
    align-items: center;
    gap: 24px;
    padding: 20px;
  }
  .risk-badge {
    width: 90px;
    height: 90px;
    border-radius: 50%;
    display: flex;
    align-items: center;
    justify-content: center;
    flex-direction: column;
    color: white;
    font-weight: 700;
    flex-shrink: 0;
  }
  .risk-badge .score { font-size: 28px; }
  .risk-badge .score-label { font-size: 9px; text-transform: uppercase; }
  .risk-details { flex: 1; }
  .risk-category {
    font-size: 18px;
    font-weight: 700;
    margin-bottom: 8px;
  }
  .risk-stats {
    display: flex;
    gap: 20px;
    flex-wrap: wrap;
  }
  .risk-stat {
    text-align: center;
    padding: 6px 14px;
    border-radius: 4px;
    background: var(--gray-50);
  }
  .risk-stat .stat-num {
    font-size: 22px;
    font-weight: 700;
  }
  .risk-stat .stat-label {
    font-size: 10px;
    color: var(--slate);
  }

  /* TABLES */
  table {
    width: 100%;
    border-collapse: collapse;
    font-size: 12px;
  }
  th {
    background: var(--gray-100);
    padding: 8px 12px;
    text-align: left;
    font-weight: 600;
    font-size: 11px;
    text-transform: uppercase;
    letter-spacing: 0.4px;
    color: var(--slate);
    border-bottom: 2px solid var(--gray-200);
  }
  td {
    padding: 8px 12px;
    border-bottom: 1px solid var(--gray-200);
    vertical-align: top;
  }
  tr:nth-child(even) { background: var(--gray-50); }

  /* BADGES */
  .badge {
    display: inline-block;
    padding: 2px 10px;
    border-radius: 12px;
    font-size: 10px;
    font-weight: 700;
    text-transform: uppercase;
    letter-spacing: 0.5px;
  }
  .badge-critical { background: var(--critical); color: white; }
  .badge-high { background: var(--high); color: white; }
  .badge-moderate { background: var(--moderate); color: white; }
  .badge-low { background: var(--low); color: white; }
  .badge-info { background: var(--info); color: white; }
  .badge-fda {
    background: #7c3aed;
    color: white;
    font-size: 9px;
    padding: 1px 6px;
  }
  .badge-cpic {
    background: var(--navy);
    color: white;
    font-size: 9px;
    padding: 1px 6px;
  }

  /* PHENOTYPE BADGES */
  .phenotype-normal { color: var(--low); font-weight: 600; }
  .phenotype-intermediate { color: var(--moderate); font-weight: 600; }
  .phenotype-poor { color: var(--critical); font-weight: 600; }
  .phenotype-ultra { color: var(--critical); font-weight: 600; }
  .phenotype-high-sens { color: var(--critical); font-weight: 600; }
  .phenotype-mod-sens { color: var(--high); font-weight: 600; }

  /* FINDING CARDS */
  .finding-card {
    border: 1px solid var(--gray-200);
    border-radius: 6px;
    margin-bottom: 16px;
    overflow: hidden;
  }
  .finding-card-header {
    display: flex;
    justify-content: space-between;
    align-items: center;
    padding: 12px 16px;
    background: var(--gray-50);
    border-bottom: 1px solid var(--gray-200);
  }
  .finding-card-header .drug-name {
    font-size: 15px;
    font-weight: 700;
  }
  .finding-card-header .gene-info {
    font-size: 12px;
    color: var(--slate);
  }
  .finding-card-body {
    padding: 16px;
  }
  .finding-row {
    display: grid;
    grid-template-columns: 120px 1fr;
    gap: 4px;
    margin-bottom: 8px;
  }
  .finding-label {
    font-size: 11px;
    font-weight: 600;
    color: var(--slate);
    text-transform: uppercase;
  }

  /* RECOMMENDATION BOX */
  .rec-box {
    border-left: 4px solid;
    padding: 12px 16px;
    margin: 12px 0;
    border-radius: 0 4px 4px 0;
  }
  .rec-box-critical { border-color: var(--critical); background: var(--critical-bg); }
  .rec-box-high { border-color: var(--high); background: var(--high-bg); }
  .rec-box-moderate { border-color: var(--moderate); background: var(--moderate-bg); }
  .rec-box-low { border-color: var(--low); background: var(--low-bg); }
  .rec-box .rec-title {
    font-weight: 700;
    font-size: 12px;
    text-transform: uppercase;
    margin-bottom: 4px;
  }
  .rec-box .rec-text { font-size: 13px; }

  /* RECOMMENDATION TABLE */
  .rec-priority {
    display: inline-block;
    width: 28px;
    height: 28px;
    border-radius: 50%;
    color: white;
    font-weight: 700;
    font-size: 14px;
    text-align: center;
    line-height: 28px;
  }
  .rec-p1 { background: var(--critical); }
  .rec-p2 { background: var(--high); }
  .rec-p3 { background: var(--moderate); }
  .rec-p4 { background: var(--low); }

  /* FOOTER */
  .report-footer {
    border-top: 2px solid var(--navy);
    padding: 16px 0;
    margin-top: 24px;
    font-size: 10px;
    color: var(--slate);
    text-align: center;
    line-height: 1.8;
  }

  /* DISCLAIMER */
  .disclaimer {
    background: var(--gray-50);
    border: 1px solid var(--gray-200);
    border-radius: 4px;
    padding: 16px;
    font-size: 11px;
    color: var(--slate);
    line-height: 1.7;
  }
  .disclaimer h4 {
    color: var(--navy);
    margin-bottom: 6px;
  }

  .evidence-legend {
    display: grid;
    grid-template-columns: repeat(3, 1fr);
    gap: 8px;
    margin-top: 12px;
  }
  .evidence-item {
    padding: 8px;
    background: var(--white);
    border: 1px solid var(--gray-200);
    border-radius: 4px;
    font-size: 11px;
  }
  .evidence-item strong { display: block; margin-bottom: 2px; }

  /* PRINT */
  @media print {
    body { font-size: 11px; }
    .page { max-width: 100%; padding: 0; }
    .section { break-inside: avoid; }
    .finding-card { break-inside: avoid; }
    .report-header { -webkit-print-color-adjust: exact; print-color-adjust: exact; }
    .badge, .rec-priority, .risk-badge { -webkit-print-color-adjust: exact; print-color-adjust: exact; }
  }
</style>
</head>
<body>

<!-- HEADER -->
<div class="report-header">
  <div>
    <div class="company-name">PGx Clinical Solutions</div>
    <div class="company-sub">Clinical Pharmacogenomics Interpretation Report</div>
    <div class="company-sub">Ernest Moyo | Rangarirai Makuku | Tapiwa Mupereki | Ngonidzashe Faya</div>
  </div>
  <div class="report-meta">
    <div class="report-id">RPT-PGX019-20260208</div>
    <div>Generated: February 08, 2026 at 06:13 AM</div>
    <div>Version 1.0.0</div>
  </div>
</div>
<div class="confidential-bar">CONFIDENTIAL — FOR CLINICAL USE ONLY — PROTECTED HEALTH INFORMATION</div>

<div class="page">

<!-- PATIENT DEMOGRAPHICS -->
<div class="section">
  <div class="section-header">Patient Information</div>
  <div class="section-body">
    <div class="demographics-grid">
      <div class="demo-item">
        <div class="demo-label">Patient Name</div>
        <div class="demo-value">Anderson, Patricia</div>
      </div>
      <div class="demo-item">
        <div class="demo-label">Patient ID (MRN)</div>
        <div class="demo-value">PGX019</div>
      </div>
      <div class="demo-item">
        <div class="demo-label">Age / Sex</div>
        <div class="demo-value">68 yr / F</div>
      </div>
      <div class="demo-item">
        <div class="demo-label">Ethnicity</div>
        <div class="demo-value">Caucasian</div>
      </div>
      <div class="demo-item">
        <div class="demo-label">Weight</div>
        <div class="demo-value">82 kg</div>
      </div>
      <div class="demo-item">
        <div class="demo-label">Primary Diagnosis</div>
        <div class="demo-value">Atrial Fibrillation, Hypertension, Hyperlipidemia</div>
      </div>
      <div class="demo-item">
        <div class="demo-label">Therapeutic Area</div>
        <div class="demo-value">Cardiology</div>
      </div>
      <div class="demo-item">
        <div class="demo-label">Reason for Testing</div>
        <div class="demo-value" style="font-size:11px;">Warfarin dose requirements unusually low (2mg/day); statin myalgia</div>
      </div>
    </div>
  </div>
</div>

<!-- EXECUTIVE RISK SUMMARY -->
<div class="section">
  <div class="section-header">Executive Summary — Risk Assessment</div>
  <div class="section-body">
    <div class="risk-banner">
      <div class="risk-badge" style="background:
        var(--critical)
        ;">
        <div class="score">100</div>
        <div class="score-label">Risk Score</div>
      </div>
      <div class="risk-details">
        <div class="risk-category" style="color:
          var(--critical)
          ;">
          Critical - Immediate Action Required
        </div>
        <div class="risk-stats">
          <div class="risk-stat">
            <div class="stat-num" style="color:var(--critical)">1</div>
            <div class="stat-label">Critical</div>
          </div>
          <div class="risk-stat">
            <div class="stat-num" style="color:var(--high)">2</div>
            <div class="stat-label">High</div>
          </div>
          <div class="risk-stat">
            <div class="stat-num" style="color:var(--moderate)">0</div>
            <div class="stat-label">Moderate</div>
          </div>
          <div class="risk-stat">
            <div class="stat-num">3</div>
            <div class="stat-label">Total Findings</div>
          </div>
          <div class="risk-stat">
            <div class="stat-num">3</div>
            <div class="stat-label">Actionable</div>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>

<!-- CURRENT MEDICATIONS -->
<div class="section">
  <div class="section-header">Current Medications Analyzed</div>
  <div class="section-body">
    <table>
      <thead>
        <tr><th>#</th><th>Medication</th><th>PGx Finding</th><th>Status</th></tr>
      </thead>
      <tbody>
        
        
        
        
          
        
          
        
        <tr>
          <td>1</td>
          <td><strong>Warfarin</strong></td>
          <td>
            
              
              <span class="badge badge-critical">CRITICAL</span>
              
              <span class="badge badge-high">HIGH</span>
              
            
          </td>
          <td>
            
              
              Gene Drug Interaction, 
              
              Gene Drug Interaction
              
            
          </td>
        </tr>
        
        
        
        
          
        
        <tr>
          <td>2</td>
          <td><strong>Simvastatin</strong></td>
          <td>
            
              
              <span class="badge badge-high">HIGH</span>
              
            
          </td>
          <td>
            
              
              Gene Drug Interaction
              
            
          </td>
        </tr>
        
        
        
        
        <tr>
          <td>3</td>
          <td><strong>Metoprolol</strong></td>
          <td>
            
              <span style="color:var(--low);">No actionable findings</span>
            
          </td>
          <td>
            
              Standard dosing appropriate
            
          </td>
        </tr>
        
        
        
        
        <tr>
          <td>4</td>
          <td><strong>Lisinopril</strong></td>
          <td>
            
              <span style="color:var(--low);">No actionable findings</span>
            
          </td>
          <td>
            
              Standard dosing appropriate
            
          </td>
        </tr>
        
        
        
        
        <tr>
          <td>5</td>
          <td><strong>Amlodipine</strong></td>
          <td>
            
              <span style="color:var(--low);">No actionable findings</span>
            
          </td>
          <td>
            
              Standard dosing appropriate
            
          </td>
        </tr>
        
        
        
        
        <tr>
          <td>6</td>
          <td><strong>Aspirin</strong></td>
          <td>
            
              <span style="color:var(--low);">No actionable findings</span>
            
          </td>
          <td>
            
              Standard dosing appropriate
            
          </td>
        </tr>
        
      </tbody>
    </table>
  </div>
</div>

<!-- GENOTYPE RESULTS -->
<div class="section">
  <div class="section-header">Pharmacogenomic Genotype Results</div>
  <div class="section-body">
    <table>
      <thead>
        <tr><th>Gene</th><th>Diplotype / Variant</th><th>Phenotype</th><th>Clinical Significance</th></tr>
      </thead>
      <tbody>
        
        
        <tr>
          <td><strong>CYP2C19</strong></td>
          <td>*1/*1</td>
          <td>
            <span class="
              phenotype-normal
              ">
              Normal Metabolizer
            </span>
          </td>
          <td>
            
              Standard enzyme activity / drug response expected
            
          </td>
        </tr>
        
        
        <tr>
          <td><strong>CYP2D6</strong></td>
          <td>*1/*1</td>
          <td>
            <span class="
              phenotype-normal
              ">
              Normal Metabolizer
            </span>
          </td>
          <td>
            
              Standard enzyme activity / drug response expected
            
          </td>
        </tr>
        
        
        <tr>
          <td><strong>CYP2C9</strong></td>
          <td>*2/*2</td>
          <td>
            <span class="
              phenotype-poor
              ">
              Poor Metabolizer
            </span>
          </td>
          <td>
            
              Absent or greatly reduced enzyme activity — significant drug impact
            
          </td>
        </tr>
        
        
        <tr>
          <td><strong>VKORC1</strong></td>
          <td>-1639G&gt;A</td>
          <td>
            <span class="
              phenotype-mod-sens
              ">
              Moderate Sensitivity
            </span>
          </td>
          <td>
            
              Increased drug sensitivity — dose adjustment likely needed
            
          </td>
        </tr>
        
        
        <tr>
          <td><strong>SLCO1B1</strong></td>
          <td>*1a/*5</td>
          <td>
            <span class="
              phenotype-intermediate
              ">
              Intermediate Function
            </span>
          </td>
          <td>
            
              Reduced enzyme activity — some drugs may need dose adjustment
            
          </td>
        </tr>
        
      </tbody>
    </table>
  </div>
</div>

<!-- GENE-DRUG INTERACTION FINDINGS -->

<div class="section">
  <div class="section-header">Gene-Drug Interaction Analysis</div>
  <div class="section-body">
    
    <div class="finding-card">
      <div class="finding-card-header">
        <div>
          <span class="drug-name">Warfarin</span>
          <span class="gene-info">— CYP2C9 (Poor Metabolizer)</span>
        </div>
        <div>
          <span class="badge badge-critical">CRITICAL</span>
          <span class="badge badge-fda">FDA LABEL</span>
          <span class="badge badge-cpic">CPIC Level A</span>
        </div>
      </div>
      <div class="finding-card-body">
        <div class="finding-row">
          <span class="finding-label">Diplotype</span>
          <span>*2/*2</span>
        </div>
        <div class="finding-row">
          <span class="finding-label">Clinical Effect</span>
          <span>CYP2C9 Poor Metabolizer: Greatly reduced S-warfarin clearance; 50-80% dose reduction typically needed</span>
        </div>
        
        <div class="finding-row">
          <span class="finding-label">Mechanism</span>
          <span>CYP2C9 is the primary enzyme for S-warfarin metabolism (the more potent enantiomer). Reduced function variants decrease warfarin clearance.</span>
        </div>
        
        
        <div class="finding-row">
          <span class="finding-label">Consequence</span>
          <span><strong>Severe bleeding; supratherapeutic INR; hemorrhage</strong></span>
        </div>
        

        <div class="rec-box rec-box-critical">
          <div class="rec-title">Recommendation</div>
          <div class="rec-text">Reduce starting dose to 1-2 mg/day. Use pharmacogenomic dosing algorithm incorporating both CYP2C9 and VKORC1 status. Frequent INR monitoring essential.</div>
        </div>

        
        <div class="finding-row">
          <span class="finding-label">References</span>
          <span style="font-size:11px;color:var(--slate);">
            Johnson JA, et al. Clin Pharmacol Ther. 2017;102(3):397-404
          </span>
        </div>
        
      </div>
    </div>
    
    <div class="finding-card">
      <div class="finding-card-header">
        <div>
          <span class="drug-name">Warfarin</span>
          <span class="gene-info">— VKORC1 (Moderate Sensitivity)</span>
        </div>
        <div>
          <span class="badge badge-high">HIGH</span>
          <span class="badge badge-fda">FDA LABEL</span>
          <span class="badge badge-cpic">CPIC Level A</span>
        </div>
      </div>
      <div class="finding-card-body">
        <div class="finding-row">
          <span class="finding-label">Diplotype</span>
          <span>-1639G&gt;A</span>
        </div>
        <div class="finding-row">
          <span class="finding-label">Clinical Effect</span>
          <span>VKORC1 Moderate Sensitivity: Increased warfarin sensitivity; lower dose requirement</span>
        </div>
        
        <div class="finding-row">
          <span class="finding-label">Mechanism</span>
          <span>VKORC1 encodes vitamin K epoxide reductase, the direct target of warfarin. Variants affect warfarin sensitivity and dose requirements.</span>
        </div>
        
        
        <div class="finding-row">
          <span class="finding-label">Consequence</span>
          <span><strong>Bleeding risk if standard doses used</strong></span>
        </div>
        

        <div class="rec-box rec-box-high">
          <div class="rec-title">Recommendation</div>
          <div class="rec-text">Reduce starting dose to 3-4 mg/day. Use pharmacogenomic dosing algorithm. Monitor INR at least weekly initially.</div>
        </div>

        
        <div class="finding-row">
          <span class="finding-label">References</span>
          <span style="font-size:11px;color:var(--slate);">
            Johnson JA, et al. Clin Pharmacol Ther. 2017;102(3):397-404<br>FDA Label: Coumadin (warfarin) - Pharmacogenomic dosing table
          </span>
        </div>
        
      </div>
    </div>
    
    <div class="finding-card">
      <div class="finding-card-header">
        <div>
          <span class="drug-name">Simvastatin</span>
          <span class="gene-info">— SLCO1B1 (Intermediate Function)</span>
        </div>
        <div>
          <span class="badge badge-high">HIGH</span>
          <span class="badge badge-fda">FDA LABEL</span>
          <span class="badge badge-cpic">CPIC Level A</span>
        </div>
      </div>
      <div class="finding-card-body">
        <div class="finding-row">
          <span class="finding-label">Diplotype</span>
          <span>*1a/*5</span>
        </div>
        <div class="finding-row">
          <span class="finding-label">Clinical Effect</span>
          <span>SLCO1B1 Intermediate Function: Increased simvastatin exposure; elevated myopathy risk</span>
        </div>
        
        <div class="finding-row">
          <span class="finding-label">Mechanism</span>
          <span>SLCO1B1 encodes hepatic uptake transporter OATP1B1. Reduced function increases systemic statin exposure and myopathy risk.</span>
        </div>
        
        
        <div class="finding-row">
          <span class="finding-label">Consequence</span>
          <span><strong>Myopathy risk; muscle pain; CK elevation</strong></span>
        </div>
        

        <div class="rec-box rec-box-high">
          <div class="rec-title">Recommendation</div>
          <div class="rec-text">Avoid simvastatin doses &gt;20 mg/day OR switch to rosuvastatin or pravastatin.</div>
        </div>

        
        <div class="finding-row">
          <span class="finding-label">References</span>
          <span style="font-size:11px;color:var(--slate);">
            Cooper-DeHoff RM, et al. Clin Pharmacol Ther. 2022;111(5):1007-1021<br>SEARCH Collaborative Group. Lancet. 2008;372(9635):270-278
          </span>
        </div>
        
      </div>
    </div>
    
  </div>
</div>


<!-- DRUG-DRUG INTERACTIONS -->


<!-- ORGAN FUNCTION WARNINGS -->


<!-- PRIORITIZED RECOMMENDATIONS -->

<div class="section">
  <div class="section-header">Prioritized Clinical Recommendations</div>
  <div class="section-body">
    
    <div style="display:flex; gap:14px; align-items:flex-start; margin-bottom:18px; padding-bottom:18px; border-bottom:1px solid var(--gray-200);">
      <div class="rec-priority rec-p1">1</div>
      <div style="flex:1;">
        <div style="display:flex; justify-content:space-between; align-items:center; margin-bottom:6px;">
          <div>
            <strong style="font-size:14px;">Warfarin</strong>
            <span style="color:var(--slate);"> — CYP2C9</span>
          </div>
          <div>
            <span class="badge badge-critical">ADJUST DOSE</span>
            <span class="badge" style="background:var(--gray-600);color:white;">Immediate Action</span>
          </div>
        </div>
        <div style="margin-bottom:6px;">Reduce starting dose to 1-2 mg/day. Use pharmacogenomic dosing algorithm incorporating both CYP2C9 and VKORC1 status. Frequent INR monitoring essential.</div>
        
        <div style="font-size:12px; color:var(--navy); margin-bottom:4px;">
          <strong>Dose adjustment:</strong> Major dose reduction required (see pharmacogenomic dosing table)
        </div>
        
        
        <div style="font-size:12px; color:var(--navy); margin-bottom:4px;">
          <strong>Alternatives:</strong> dose adjustment per pharmacogenomic algorithm
        </div>
        
        <div style="font-size:11px; color:var(--slate);">
          <strong>Monitoring:</strong> Monitor INR every 2-3 days until stable, then weekly. Target INR 2.0-3.0.
        </div>
        
        <div style="font-size:11px; color:var(--slate); margin-top:4px;">
          <strong>Rationale:</strong> Patient is a poor metabolizer for CYP2C9. CYP2C9 is the primary enzyme for S-warfarin metabolism (the more potent enantiomer). Reduced function variants decrease warfarin clearance. Clinical risk: Severe bleeding; supratherapeutic INR; hemorrhage. Evidence: CPIC Level A.
        </div>
        
      </div>
    </div>
    
    <div style="display:flex; gap:14px; align-items:flex-start; margin-bottom:18px; padding-bottom:18px; border-bottom:1px solid var(--gray-200);">
      <div class="rec-priority rec-p2">2</div>
      <div style="flex:1;">
        <div style="display:flex; justify-content:space-between; align-items:center; margin-bottom:6px;">
          <div>
            <strong style="font-size:14px;">Simvastatin</strong>
            <span style="color:var(--slate);"> — SLCO1B1</span>
          </div>
          <div>
            <span class="badge badge-high">SWITCH MEDICATION</span>
            <span class="badge" style="background:var(--gray-600);color:white;">Next Clinical Visit</span>
          </div>
        </div>
        <div style="margin-bottom:6px;">Avoid simvastatin doses &gt;20 mg/day OR switch to rosuvastatin or pravastatin.</div>
        
        
        <div style="font-size:12px; color:var(--navy); margin-bottom:4px;">
          <strong>Alternatives:</strong> rosuvastatin, pravastatin
        </div>
        
        <div style="font-size:11px; color:var(--slate);">
          <strong>Monitoring:</strong> Transition to alternative medication. Monitor for efficacy and tolerability at 2-4 weeks.
        </div>
        
        <div style="font-size:11px; color:var(--slate); margin-top:4px;">
          <strong>Rationale:</strong> Patient is a intermediate function for SLCO1B1. SLCO1B1 encodes hepatic uptake transporter OATP1B1. Reduced function increases systemic statin exposure and myopathy risk. Clinical risk: Myopathy risk; muscle pain; CK elevation. Evidence: CPIC Level A.
        </div>
        
      </div>
    </div>
    
  </div>
</div>


<!-- LAB VALUES -->
<div class="section">
  <div class="section-header">Relevant Laboratory Values</div>
  <div class="section-body">
    <table>
      <thead>
        <tr><th>Test</th><th>Value</th><th>Reference Range</th><th>Status</th></tr>
      </thead>
      <tbody>
        
        <tr>
          <td>eGFR</td>
          <td>58 mL/min/1.73m²</td>
          <td>≥90 mL/min/1.73m²</td>
          <td><span class="phenotype-poor">Moderate Impairment</span>
              </td>
        </tr>
        
        
        <tr>
          <td>ALT</td>
          <td>42 U/L</td>
          <td>7-40 U/L</td>
          <td><span class="phenotype-intermediate">Elevated</span>
              </td>
        </tr>
        
        
        <tr>
          <td>AST</td>
          <td>38 U/L</td>
          <td>8-33 U/L</td>
          <td><span class="phenotype-intermediate">Elevated</span>
              </td>
        </tr>
        
        
        <tr>
          <td>Serum Creatinine</td>
          <td>1.2 mg/dL</td>
          <td>0.6-1.2 mg/dL</td>
          <td><span class="phenotype-normal">Normal</span>
              </td>
        </tr>
        
        
        <tr>
          <td>INR</td>
          <td>2.8</td>
          <td>2.0-3.0 (on warfarin)</td>
          <td><span class="phenotype-normal">Therapeutic</span>
              </td>
        </tr>
        
        
        <tr>
          <td>Albumin</td>
          <td>3.6 g/dL</td>
          <td>3.5-5.5 g/dL</td>
          <td><span class="phenotype-normal">Normal</span>
              </td>
        </tr>
        
      </tbody>
    </table>
  </div>
</div>

<!-- METHODOLOGY & DISCLAIMERS -->
<div class="section">
  <div class="section-header">Methodology, Evidence, &amp; Disclaimers</div>
  <div class="section-body">
    <div class="disclaimer">
      <h4>Clinical Interpretation Methodology</h4>
      <p>This report was generated using clinical pharmacogenomics guidelines from the Clinical Pharmacogenetics Implementation Consortium (CPIC), FDA pharmacogenomic labeling, and PharmGKB clinical annotations. Drug-drug interaction analysis includes phenoconversion assessment where concomitant medications may alter functional enzyme activity.</p>

      <h4 style="margin-top:12px;">Evidence Level Legend</h4>
      <div class="evidence-legend">
        <div class="evidence-item">
          <strong>CPIC Level A</strong>
          Strong evidence. Prescribing action recommended based on preponderance of evidence from clinical studies.
        </div>
        <div class="evidence-item">
          <strong>CPIC Level B</strong>
          Moderate evidence. Prescribing action may be considered based on available evidence.
        </div>
        <div class="evidence-item">
          <strong>CPIC Level C</strong>
          Optional. Evidence is limited; clinical action based on expert opinion.
        </div>
      </div>

      <h4 style="margin-top:12px;">Important Disclaimers</h4>
      <ul style="margin-left:16px; margin-top:4px;">
        <li>This report is intended to <strong>support, not replace</strong>, clinical judgment by qualified healthcare professionals.</li>
        <li>Genetic test results should be interpreted in the context of the patient's complete clinical picture, including comorbidities, organ function, and concomitant medications.</li>
        <li>Pharmacogenomic recommendations may change as new evidence emerges. This report reflects guidelines current as of the report generation date.</li>
        <li>Not all genetic variants affecting drug metabolism have been characterized. A "normal metabolizer" result does not guarantee typical drug response.</li>
        <li>Environmental factors (diet, smoking, supplements) may also influence drug metabolism and are not captured in genetic testing.</li>
      </ul>

      <h4 style="margin-top:12px;">Data Privacy</h4>
      <p>This report contains Protected Health Information (PHI) governed by HIPAA. Distribution is limited to authorized healthcare personnel involved in the patient's care. Do not transmit via unsecured channels.</p>
    </div>
  </div>
</div>

</div><!-- end .page -->

<!-- FOOTER -->
<div class="report-footer">
  <div class="page">
    <strong>PGx Clinical Solutions</strong> — Clinical Pharmacogenomics Interpretation Services<br>
    Report RPT-PGX019-20260208 | Generated February 08, 2026 at 06:13 AM | Platform v1.0.0<br>
    Ernest Moyo | Rangarirai Makuku | Tapiwa Mupereki | Ngonidzashe Faya<br>
    This document is confidential and intended solely for the use of the addressee.
  </div>
</div>

</body>
</html>